The combination of navelbine and epirubicin as neoadjuvant chemotherapy in the treatment of locally advanced breast cancer
- VernacularTitle:去甲长春花碱加表柔比星新辅助化疗方案治疗局部晚期乳腺癌的临床研究
- Author:
Canming CHEN
;
Kunwei SHEN
;
Jiong WU
- Publication Type:Journal Article
- Keywords:
neoadjuvant chemotherapy;
local advanced breast cancer;
navelbine;
epirubicin
- From:China Oncology
1998;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose: To evaluate the efficacy and toxicity of Navelbine( NVB) and Epirubicin ( Epi -ADM) as the neoadjuvant chemotherapy in the treatment of locally advanced breast cancer. Methods: From September 2001 to February, 2003, 76 cases, LABC patients ( II b ~ HI b ) were treated with NE chemotherapy before operation. Neoadjuvant chemotherapy regimens containing vinorelbine( N), 25 mg/m (days 1 and 8) and epirubicin( E), 60 mg/m (days 1) were administered every 3 weeks for three cycles before local treatment. The response in the primary tumor and the regional lymph nodes and the chemotherapy toxicity were observed for each patient. Results: The response in the primary tumor: clinical objective response was 84. 2% (19.7% (15/76) CR and 64. 5% (49/76) PR) , 14. 5% (11/76) SD and 1.3% (1/76) PD. Pathological complete response was found in 11 cases( 14. 5%). 9 cases (28. 1%) who have positive FNA result in the regional lymph node before chemotherapy showed negative result in the surgery specimen. The most common toxicities are leukocytopenia, nausea/vomiting and alopecia. Leucopenia grade 3-4 was reported in 54. 2% of the patients but there were no chemotherapy related toxic deaths. Conclusions: The combination of Vinorelbine and Epirubicin is a very active and well-tolerated regimen as neoadjuvant chemotherapy for the LABC.
